DILIsym: Using QST Predictions to Optimize Your Drug, De-Risk Your Regulatory Submission, and Guide R&D
January 25, 2024 - 11am ET | Virtual Event (recording available following the live event)
Hear from liver safety expert Dr. Paul B. Watkins, a distinguished professor at the UNC Eshelman School of Pharmacy, Dr. Brett Howell, President of Quantitative Systems Pharmacology Solutions at Simulations Plus, and Dan Legault, CEO of Antibe Therapeutics.
The DILIsym® liver safety prediction platform is a quantitative systems toxicology (QST) tool used for liver safety assessment, and can be utilized at any time during drug development. It serves to provide insight about compounds and de-risks them for regulatory submissions. In this webinar, you’ll learn how several DILIsym clients have strategically used its sophisticated capabilities to overcome challenges and achieve their development goals.